Article Text
Statistics from Altmetric.com
Key learning points
There has been a rapid increase in the use of glucagon-like peptide (GLP-1) receptor agonists for weight loss.
Studies have reported increased risks of adverse gastrointestinal (GI) events in people with diabetes treated with GLP-1 agonists.
A cohort study found that GLP-1 agonists used for weight loss are associated with increased risk of pancreatitis, bowel obstruction and delayed stomach emptying compared with bupropion-naltrexone.
A cohort study highlighted increased risks of serious gastrointestinal adverse events associated with glucagon-like peptide (GLP-1) receptor agonists used for weight loss compared with bupropion-naltrexone.1
Overview
This cohort study used prescription and diagnostic data for 16 million patients in the USA from 2006 to 2020 to examine gastrointestinal events associated with the use of …
Footnotes
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.